CNASHighly Regulated (List I)TranslatedFRAGMINE
PFIZER
Identification
- Active ingredient (INN)
- DALTEPARINE SODIQUE
- Internal code
- 12 B 169
- Country of Origin
- France
- Pharmaceutical form
- Injectable Solution (Pre-filled Syringe)
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/02 seringues pre-remplies 1ml
CNASDAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
This heparin is low molecular weight heparin (HBPM) with the following indications: Adult population.
- Treatment of deep venous thrombosis (DVT) formed.
- Treatment of unstable angina and myocardial infarction without Q-wave in acute phase in combination with aspirin.
- Prevention of coagulation of the extracorporal circulation circuit during haemodialysis (general session of ≤ 4 hours).
Paediatric population
Treatment of symptomatic venous thromboembolism (VTE) in paediatric patients 1 month of age and older.
Associated Conditions
Although the various treatments for heparin-like drugs, including the low-molecular-weight drugs, have been used in the following ways: (a) the low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low-risk, low.
Mechanism of Action
The following are the results of the study: odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsis, odepsistic, odepsistic, odepsistic, odepsistic, odop.
Adverse Effects
Approximately 3% of patients receiving prophylaxis have been reported as having side effects.
Reported adverse reactions that may be related to dalteparin sodium are listed below by system organ classification and frequency: common ( 3 1/100, < 1/10), uncommon ( 3 1/1,000, < 1/100), rare ( 3 1/10,000).
System organ class Frequency Adverse reactions
Blood and lymphatic disorders Common Moderate thrombopenia (Type I), generally reversible during treatment Indeterminate* Heparin-induced immunoallergic thrombocytopenia (Type II, with or without associated thrombotic complications) Immune system disorders Uncommon hypersensitivity and peripheral procedures Absence of absorbent disorder or absorbent disorder of absorbent disorder of absorbent disorder of absorbent disorder of absorbent disorder of absorbent disorder of absorbent disorder of absorbent disorder of absorbent disorder of absorbsorbsorbs or absorbsorbsorbsorbsorbsorbs.